ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

Market Cap	2.22B -10.2%
Revenue (ttm)	862.85M +2.9%
Net Income	17.80M -48.1%
EPS	0.07 -48.8%
Shares Out	256.06M
PE Ratio	119.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,560,620
Open	8.35
Previous Close	8.49
Day's Range	8.35 - 8.75
52-Week Range	7.69 - 15.20
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsule...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,162
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300254

Financial Performance

In 2025, SHE:300254's revenue was 870.79 million, an increase of 2.86% compared to the previous year's 846.61 million. Earnings were 24.85 million, a decrease of -41.10%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error